Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBR854 Combined With Pazopanib in Advanced Renal Cell Carcinoma
NCT07087158Phase 2Recruiting
- Sponsor
- Imbioray
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Other Engineered Cells
- Countries
- 1
01
Overview
A Phase 2 trial of IBR854 in renal cell carcinoma (RCC), sponsored by Imbioray. Started Sep 2025; status: recruiting.
02
Drugs
IBR854
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07087158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087158.